



Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

February 5, 2013

CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 15th Annual BIO CEO and Investor Conference on Tuesday, February 12, 2013 at 11:30 AM ET. The conference is being held at the Waldorf Astoria Hotel in New York City. A live webcast of the presentation will be available at www.protalix.com on the event calendar page. A replay will be archived and available after the conclusion of the presentation for 30 days.

About the BIO CEO & Investor Conference

The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year's conference will feature corporate presentations from more than 140 leading biotechnology and pharmaceutical companies, Fireside Chats with industry leaders, four Therapeutic Workshops and three Business Roundtables all drawing from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber private companies will be presenting at the event, and plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), an enzyme replacement therapy for the treatment of Gaucher disease, was approved for marketing by the U.S. Food and Drug Administration in May 2012, and by Israel's Ministry of Health in September 2012. Additional marketing applications for taliglucerase alfa have been filed in other countries. Protalix is partnered with Pfizer Inc. for worldwide development and commercialization, excluding Israel, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.

CONTACT: Investor Contact

Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com

Media Contact

Kari Watson
MacDougall Biomedical Communications
781-235-3060
kwatson@macbiocom.com

Protalix BioTherapeutics, Inc.